A Study of RSLV-132 in Females With Sjögren's Disease

Conditions

• Primary Sjögren Syndrome

Eligibility Criteria

Sex

FEMALE

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• RSLV-132 — DRUG
  Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
• Placebo — DRUG
  0.9% sodium chloride solution

Study Details

The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS. Participants will: Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device

Key Dates

Start date

Dec 1, 2024

Status verified

Jul 2025

Primary completion

Dec 1, 2026

Completion

Mar 1, 2027

Study Design

Enrollment

106 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: RSLV-132
  Intravenous infusions of 10 mg/kg RSLV-132 solution on Days 1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, and 155) for a total of 22 weeks of treatment
• Placebo Comparator: Placebo
  Intravenous infusions of placebo solution on Days 1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, and 155) for a total of 22 weeks of treatment

Primary Outcome Measure

Assessment of cardinal symptoms of Sjogren's [ Time Frame: Measured daily from at least 7 days prior to first dose until 169 days after the first dose ]

Central Contacts

• PatientWing https://app.patientwing.com/campaign/clinicaltrials.gov
  (213) 459-2979
  [email protected]

Locations (24)

Find similar trials in Chula Vista, CA